Sebastian M. Schmidt, Tobias Ankermann, Carl-Peter Bauer, Peter Fischer, Monika Gappa, Michael Gerstlauer, Matthias V. Kopp, Susanne Lau, Christiane Lex, Bernd Mischo, Bianca Schaub, Thomas Spindler, Christian Vogelberg

• The extension of the approval of dupilumab for the treatment of severe atopic dermatitis in children 6 months of age and older in Germany creates a potential conflict with the administration of live attenuated vaccines. According to the product information, the administration of live attenuated vaccines is contraindicated during ongoing dupilumab therapy. This position paper, written by specialists in pediatric immunology and allergology from Germany and Switzerland, aims to support pediatricians to provide their patients with the best possible treatment with dupilumab and appropriate vaccinations based on the currently available evidence, including statements and advice for clinical situations. The practical implementation of these statements requires a differentiated approach. The position paper covers the situation in Germany, with special attention to the recommendations of the STIKO (Standing Committee on Vaccination) and the Robert Koch Institute for German-speaking countries and the legal situation here.